A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) (NCT04951219)

🧪 Interventions in This Study

• Resmetirom (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (76 Sites)

Showing the first 25 of 76 sites.

• Central Research Associates — Birmingham, Alabama
• Arizona Liver Health - Chandler — Chandler, Arizona
• East Valley Family Physicians — Chandler, Arizona
• The Institute For Liver Health - Glendale — Glendale, Arizona
• The Institute For Liver Health - Tucson — Tucson, Arizona
• Adobe Gastroenterology — Tucson, Arizona
• Arkansas Gastroenterology — North Little Rock, Arkansas
• Fresno Clinical Research Center — Fresno, California
• National Research Institute - Huntington Park — Huntington Park, California
• Ruane Clinical Research Group — Los Angeles, California
• Cedars-Sinai Medical Center — Los Angeles, California
• National Research Institute - Los Angeles — Los Angeles, California
• National Research Institute - Panorama City — Panorama City, California
• San Fernando Valley Health Institute — West Hills, California
• South Denver Gastroenterology - Swedish Medical Center Office — Englewood, Colorado
• Excel Medical Clinical Trials — Boca Raton, Florida
• Covenant Research — Fort Myers, Florida
• Velocity Clinical Research, Hallandale Beach (MD Clinical) — Hallandale, Florida
• Floridian Clinical Research — Hialeah, Florida
• Nature Coast Clinical Research - Inverness — Inverness, Florida
• Jacksonville Center for Clinical Research — Jacksonville, Florida
• Florida Research Institute — Lakewood Rch, Florida
• Floridian Clinical Research — Miami Lakes, Florida
• Orlando Research Center — Orlando, Florida
• Progressive Medical Research — Port Orange, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-Alcoholic Fatty Liver Disease

• Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis — Chula Vista, California
• Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk — St Louis, Missouri
• A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) — Chandler, Arizona
• SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease — Chicago, Illinois
• The Olmsted NAFLD Epidemiology Study (TONES) — Rochester, Minnesota

Explore by condition: All Non-Alcoholic Fatty Liver Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.